spacer
home > ebr > summer 2003 > biopharmaceutical characterisation - considering key questions
PUBLICATIONS
European Biopharmaceutical Review

Biopharmaceutical Characterisation - Considering Key Questions

In the race to bring new biotech derived products to market, researchers face many obstacles along the road from discovery to commercial success. So, any new analytical techniques which can help smooth the path, particularly through the regulatory approval stages, are always welcome. One such breakthrough has been the use of mass spectrometry (MS) to provide information about the primary protein and carbohydrate structure of biomolecules. MS techniques are now being applied routinely to the characterisation of products ranging in size and complexity from small synthetic peptides to conjugated antibody molecules. However, with the bewildering array of modern analytical instruments available, it is sometimes difficult to choose the most suitable strategies to use for a particular characterisation problem, or indeed decide if or when these studies should be performed. This article intends to address some of the frequently asked questions about biopharmaceutical characterisation using mass spectrometry.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Fiona M Greer, Director, Biochemical Services at M-Scan Ltd

Following a PhD in Protein Biochemistry from Aberdeen University, Fiona Greer joined M-Scan in 1984 to develop analytical services using the then new techniques of biopolymer mass spectrometry. She is Director of Biochemistry and VP of M-Scan Ltd, M-Scan SA and M-Scan Inc, and is also responsible for QA at all three laboratories.

spacer
Dr Fiona M Greer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mr Turhan Ozen Chief Cargo Officer at Turkish Airlines elected to the International Air Cargo Association (TIACA) Committee

Turhan Ozen, serving as Chief Cargo Officer at the global brand Turkish Airlines, was elected to the International Air Cargo Association (TIACA) Committee, the joint voice of the industry that aims to enhance the air cargo profile with intensive efforts towards the global standards.
More info >>

White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>

 
Industry Events

PDA Europe Annual Meeting 2019

24 June 2019, Hilton Amsterdam

Featuring updates from international regulatory agencies as well as industry, this promises to become another highlight in the 2019 event calendar and is a meeting not to be missed!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement